Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
Dudding T, Haworth S, Lind PA, Sathirapongsasuti JF, Tung JY, Mitchell R, Colodro-Conde L, Medland SE, Gordon S, Elsworth B, Paternoster L, Franks PW, Thomas SJ, Martin NG, Timpson NJ. Genome wide analysis for mouth ulcers identifies associations at immune regulatory loci. Nat Commun. 2019 03 05; 10(1):1052.
-
Okhovat JP, Tahan SR, Kim CC. A pink enlarging plaque on the plantar foot: amelanotic acral lentiginous melanoma. Dermatol Online J. 2019 Jan 15; 25(1).
-
Friese MB, Nathan M, Culley DJ, Crosby G. Isoflurane anesthesia impairs the expression of immune neuromodulators in the hippocampus of aged mice. PLoS One. 2018; 13(12):e0209283.
-
Plesch E, Chen CC, Butz E, Scotto Rosato A, Krogsaeter EK, Yinan H, Bartel K, Keller M, Robaa D, Teupser D, Holdt LM, Vollmar AM, Sippl W, Puertollano R, Medina D, Biel M, Wahl-Schott C, Bracher F, Grimm C. Selective agonist of TRPML2 reveals direct role in chemokine release from innate immune cells. Elife. 2018 11 27; 7.
-
Yamout BI, El-Ayoubi NK, Nicolas J, El Kouzi Y, Khoury SJ, Zeineddine MM. Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study. J Immunol Res. 2018; 2018:9084759.
-
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018 11 08; 379(19):1811-1822.
-
Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation. N Engl J Med. 2018 11 08; 379(19):1846-1850.
-
Mengel D, Fraune L, Sommer N, Stettner M, Reese JP, Dams J, Glynn RJ, Balzer-Geldsetzer M, Dodel R, Tackenberg B. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. Muscle Nerve. 2018 11; 58(5):681-687.
-
Wallwork R, Wallace Z, Perugino C, Sharma A, Stone JH. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore). 2018 Oct; 97(42):e12631.
-
Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N Engl J Med. 2018 09 13; 379(11):1017-1027.